BIAF News and Press, bioAffinity Technologies Inc.

A look at the top 10 most actives in the United States iSpecimen Inc. (ISPC) rose 27.0% to $0.2844 on volume of 264,529,162 shares bioAffinity Technologies Inc. (BIAF) rose 98.1% to $2.12 on volume of 238,230,568 shares Functional Brands Inc. (MEHA) rose 0.9% to $0.193 on volume of 185,024,...

2026-03-13 15:15:54 ET More on bioAffinity Technologies Financial information for bioAffinity Technologies Read the full article on Seeking Alpha For further details see: bioAffinity Technologies GAAP EPS of -$8.66, revenue of $6.2M

A look at the top 10 most actives in the United States iSpecimen Inc. (ISPC) rose 77.1% to $0.3968 on volume of 159,189,677 shares bioAffinity Technologies Inc. (BIAF) rose 115.4% to $2.305 on volume of 87,353,377 shares CXApp Inc. (CXAI) rose 33.1% to $0.2928 on volume of 76,335,147 shares...

Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company’s high-value CyPath® Lung test Number of CyPath® Lung tests performed in 2025 increased by 99% compared to 2024 Orders for CyPath® Lung by...

Study to evaluate clinical performance of CyPath® Lung for the early detection of lung cancer in high-risk patients Murtha Cancer Center Research Program at Uniformed Services University of the Health Sciences provides support for longitudinal study bioAffinity ...

Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Research demonstrates the technology’s ability to identify drug antibody receptors in sputum for two leading asthma therapies ...

Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) , a biotechnology company focused on noninvasive diagnostics and early cancer detection, today annou...

CyPath® Lung test supported recommendation for surveillance strategy, rather than subjecting elderly patient to an invasive, risky and costly biopsy procedure Despite a suspicious nodule during a low-dose CT scan, a repeat scan showed no nodules in the lungs, validating the decis...

Noninvasive CyPath® Lung test has shown 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules less than 2 centimeters Case study highlights how CyPath® Lung reduces patient anxiety and supports physician confidence in assessment of beni...

Advisory Board provides independent guidance on strategic priorities, including growing adoption of the Company’s noninvasive CyPath ® Lung diagnostic test bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) , a biotechnology company focused on nonin...